Introduction
============

Transforming growth factor β (TGF-β1) is a pleiotropic cytokine, which has been demonstrated to regulate a wide array of biological processes. It plays a major role in the regulation of vascular function and hemostasis. Therefore, it can be considered as a putative therapeutic target in disorders of the blood--vessel interface, such as atherosclerosis and myeloproliferative syndromes. The present narrative review highlights the most important advances in the knowledge of TGF-β regulation in cardiovascular disease. This review has been prepared after a comprehensive search through MEDLINE. Search terms were "TGF beta", "cardiovascular", "atherosclerosis", "myeloproliferative syndromes", "pathway", and "regulation". A broader coverage of research strategy can be found in Gasparyan et al.[@b1-vhrm-8-533]

Regulation of TGF-β1 physiology
===============================

The canonical TGF-β1 pathway
----------------------------

The regulation of TGF-β1 is shown in [Figure 1](#f1-vhrm-8-533){ref-type="fig"}. Briefly, active TGF-β1 is released from its latency-associated peptide by activating proteases. Then, it binds to the TGF-β-RII, which acts as a Ser/Thre kinase.[@b2-vhrm-8-533] This Ser/Thre kinase activity phosphorylates TGF-β-RI which may be present in several isoforms termed activinlike kinases (ALKs).[@b3-vhrm-8-533] In general, TGF-β1 stimulates ALK-5 and phosphorylates second messenger proteins termed Smads.[@b4-vhrm-8-533] Smad2 or Smad3 form a heterodimer with Smad4, and internalize into the nucleus to decrease the proliferation/apoptosis ratio,[@b5-vhrm-8-533] increase differentiation,[@b6-vhrm-8-533] and inhibit the expression of inflammatory molecules.[@b7-vhrm-8-533] In endothelial cells, TGF-β1 can stimulate ALK-4/5/7 and Smad2/3, or stimulate ALK-1 and Smad1/5/8 and increase cell proliferation.[@b8-vhrm-8-533] Smad6 and 7 are inhibitory Smads, since they bind Smad4 and inhibit its internalization into the nucleus.[@b9-vhrm-8-533] Endoglin is an accessory to the TGF-β receptor that seems to modulate receptor binding and ALK stimulation.[@b10-vhrm-8-533] It is mutated in hereditary hemorrhagic telangiectasia type 1,[@b11-vhrm-8-533] whereas ALK-1 is mutated in hereditary hemorrhagic telangiectasia type 2.[@b12-vhrm-8-533]

In addition to this classical Smad-dependent pathway, other crosstalks have been described among TGF-β1 and several signaling pathways,[@b13-vhrm-8-533] including mitogen-activated protein (MAP) kinases[@b14-vhrm-8-533] and small GTPases, such as RhoA.[@b15-vhrm-8-533] Non-Smad pathways seem to be especially important to regulate the TGF-β-mediated fibrotic effect. In particular, focal adhesion kinase has been shown to regulate TGF-β-mediated fibrosis. This is mediated by a TGF-β-mediated recruitment of the p85 subunit of PI3K to focal adhesion kinase to regulate signal transduction, which is independent of tyrosine kinase activation.[@b16-vhrm-8-533] Among MAP kinases, JNK plays a necessary role in mediating TGF-β-mediated epithelial-to-mesenchymal transition in rat peritoneal fibroblasts, in cooperation with Smad3.[@b17-vhrm-8-533] In addition, the ERK MAP kinase regulates epithelial-to-mesenchymal transition in mesothelial cells by involving nuclear factor-κB (NFκB);[@b18-vhrm-8-533] Conversely, p38 MAP kinase seems to inhibit this effect in the same cell model.[@b19-vhrm-8-533] This antifibrotic effect of TGF-β is also mediated by peroxisome proliferator-activated receptor-γ by preventing p300 recruitment, subsequent histone H4 hyperacetilation, and eventual collagen synthesis.[@b20-vhrm-8-533]

New insights in TGF-β1 regulation
---------------------------------

In recent years, a growing body of experimental medicine suggests an important role of several factors which may act (in a real-time manner) as rheostats for the fine tuning of the TGF-β1 pathway, and thus adapt cell response of TGF-β1 to a given cellular circumstance.

The first important factor is receptor endocytosis. Recent reports indicate that receptor endocytosis is a key event in proper signaling and receptor recycling.[@b21-vhrm-8-533] Moreover, it has been clarified that clathrin-coated pits-mediated endocytosis enhances TGF-β function,[@b22-vhrm-8-533] and that early endosomes behave as signaling organelles to promote TGF-β signaling. Conversely, however, the lipid rafts-caveolae endocytic system inhibits TGF-β signaling.[@b23-vhrm-8-533] Interestingly, it has been described that, given that caveolae localize in cholesterol-rich membrane domains, cholesterol itself inhibits TGB-β signaling in vitro,[@b24-vhrm-8-533] and this might mediate, at least in part, atherogenic effects of cholesterol in vivo. In fact, caveolin, a protein that is a key component of caveolae, physically interacts with TGF-β-R-I to block Smad signaling.[@b25-vhrm-8-533]

The second key event is micro-RNA (miRNA) regulation.[@b26-vhrm-8-533] This is achieved by noncoding RNA fragments which are able to silence gene expression. In particular, the miRNA 200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) cooperate with TGF-β signaling to regulate epithelial-to-mesenchymal transition.[@b27-vhrm-8-533] Interestingly, other miRNAs are able to inhibit the antitumor effects of TGF-β and thus are accumulated in human tumors, as seen with the miRNA 25 cluster (miRNA 106b, miRNA 93, and miRNA 25) in gastric cancer,[@b28-vhrm-8-533] neuroblastoma, and multiple myeloma; and the miRNA 17--92 cluster (miRNA 17, miRNA 18a, miRNA 19a, miRNA 20a, miRNA 19b-1, miRNA 92a) in diffuse large B cell lymphoma and small-cell lung cancer.[@b26-vhrm-8-533] MiRNAs miRNA 106b-25 and miR-92 regulate TGF-β-mediated antiproliferative and apoptotic effects.[@b29-vhrm-8-533] In particular, miR-106b and miR-93 inhibit TGF-β-mediated cell cycle arrest, whereas miR-25 inhibits TGF-β-mediated apoptosis.[@b26-vhrm-8-533],[@b29-vhrm-8-533] Of note, this crosstalk between the TGF-β pathway and miRNA seems to be a bidirectional process. Thus, miRNA not only affects the TGF-β pathway, but also, miR-21 is directly upregulated by TGF-β1, and plays a key role in vascular smooth muscle cell differentiation.[@b30-vhrm-8-533] It is expected that this TGF-β-mediated effect also takes place in many other miRNAs. These effects seem to take place postranscriptionally by affecting the Drosha miRNA-stabilizing machinery.[@b26-vhrm-8-533] Therefore, miRNAs are plausible key regulators of the cell response of TGF-β, in a real-time and context-dependent manner.

A third emerging mechanism to control the complex regulation of TGF-β1 signaling is the cytoskeleton. Smads are tightly anchored to the cytoskeleton and constantly shuttle the cytoplasm and the nucleus in basal cell conditions.[@b31-vhrm-8-533] In fact, all Smads are associated to cell microtubules and their trafficking is controlled, at least in part, by microtubules-related proteins, such as kinesin for going to cell membrane receptors,[@b32-vhrm-8-533] and dynein when they direct to the nucleus.[@b33-vhrm-8-533] In cell culture models, nuclear accumulation of Smads has been considered to be a direct marker of TGF-β1 signaling,[@b34-vhrm-8-533],[@b35-vhrm-8-533] and this could be mediated by nuclear phosphatases, which dephosphorylate the C-terminal di-serine motifs Smads.[@b36-vhrm-8-533]

Yet again, this link between TGF-β and cytoskeleton acts in a bidirectional manner, given that TGF-β regulates actin polymerization by the non-Smad-signaling pathways RhoA and p38,[@b37-vhrm-8-533] and by affecting epithelial-to-mesenchymal transition.

In recent years, several mathematical models have been developed that will predict the cell response of TGF-β1 in a given circumstance in silico, and thus help to design target-designed novel molecules, in order to modulate the important roles exerted by TGF-β1 signaling in health and disease.[@b38-vhrm-8-533] These models are based on a network of molecular components. In order to describe how a given parameter changes with time, systems of ordinary differential equations were incorporated to build a kinetic model, since these could express molecular changes (concentrations and biochemical modifications) over time, and relate these data to empirical ones.[@b38-vhrm-8-533]

TGF-β1 in cardiovascular disease
================================

TGF-β1 in vascular and hemostasis physiology
--------------------------------------------

In general, TGF-β1 is considered as an anti-inflammatory cytokine in the vessel wall.[@b39-vhrm-8-533] In normal vessels, TGF-β1 inhibits endothelial[@b40-vhrm-8-533] and vascular smooth muscle[@b41-vhrm-8-533] cell proliferation. It also increases apoptosis to avoid excessive cellular accumulation,[@b42-vhrm-8-533] and stimulates vascular cell differentiation,[@b43-vhrm-8-533] with a parallel decrease of the expression of inflammatory molecules.[@b44-vhrm-8-533] In the blood--vessel interface, TGF-β1 decreases expression of cell adhesion molecules in vascular cells.[@b45-vhrm-8-533] In addition, in leukocytes, it decreases the activation of integrins[@b46-vhrm-8-533] and stimulates the function of endothelial progenitor cells, which may help to restore the denuded vessel wall.[@b47-vhrm-8-533] In hemostasis, TGF-β1 seems to behave as an antifibrinolytic factor[@b48-vhrm-8-533] and stimulates platelet-induced vascular repair.[@b49-vhrm-8-533] TGF-β1 is a normal component of platelet alpha granules.[@b50-vhrm-8-533] In fact, the vast majority of serum TGF-β1 comes from platelet degranulation.[@b51-vhrm-8-533]

TGF-β1 in atherosclerosis
-------------------------

In atherosclerosis, TGF-β1 is considered to be an antiatherogenic factor, especially in the early stages of the disease, according to what has been termed the protective cytokine hypothesis.[@b52-vhrm-8-533] Thus, TGF-β1 inhibits excessive vascular smooth muscle cell accumulation in the neointima,[@b53-vhrm-8-533] and avoids plaque rupture by means of its stimulation of extracellular matrix synthesis and tissue repair.[@b54-vhrm-8-533] In addition, it controls local inflammation by stimulating Th3 function and regulatory T cells (CD3^+^/CD25^+^ cells).[@b55-vhrm-8-533] Therefore, it avoids the excessive immune attack (from both innate and acquired immunity mechanisms) that characterizes atherosclerotic vascular disease. [@b56-vhrm-8-533] In the clinical arena, decreased serum levels of TGF-β1 have been correlated to clinical atherosclerosis.[@b51-vhrm-8-533] However, this parameter has remained an elusive atherosclerosis marker, given that these levels may vary according to the time course of the disease and age.[@b57-vhrm-8-533] The majority of serum TGF-β levels originate from platelets and thus are markers of platelet activation in atherosclerosis[@b2-vhrm-8-533] and rheumatoid arthritis.[@b58-vhrm-8-533] TGF-β levels can be calculated as an active or total (active and acid-activatable) form. In systemic lupus erythematous patients, a lower serum activation index has been associated with increased lymphocyte apoptosis, irreversible organ damage, disease duration, low-density lipoprotein, and increased carotid intima-media thickness.[@b59-vhrm-8-533] Endoglin is an accessory TGF-β receptor and soluble endoglin may interfere with TGF-β interaction with membrane-bound receptors and thus decrease TGF-β signaling.[@b60-vhrm-8-533] Increased levels of soluble endoglin have been related to atherosclerosis,[@b61-vhrm-8-533] as well as preeclampsia. [@b62-vhrm-8-533]

However, in late stages of the disease, TGF-β1 seems to behave as a proatherogenic factor by increasing excessive extracellular matrix,[@b63-vhrm-8-533] promotion of in-stent restenosis,[@b64-vhrm-8-533] and induction of pathologic vascular remodeling.[@b65-vhrm-8-533] In fact, it has been demonstrated that end-organ damage in hypertension has been related to increased levels of TGF-β1 in serum and urine.[@b66-vhrm-8-533] Moreover, in atherosclerotic vascular disease, it has been demonstrated that cells become insensitive to TGF-β1 signaling by means of decreased TGF-β1 activation,[@b67-vhrm-8-533] decreased receptor[@b2-vhrm-8-533],[@b68-vhrm-8-533] and Smad downregulation,[@b2-vhrm-8-533],[@b69-vhrm-8-533] altered endocytosis and intracellular trafficking pattern,[@b21-vhrm-8-533] or alteration of any of the other multiple cellular pathways that crosstalk with the TGF-β1 signaling pathway.[@b2-vhrm-8-533] Interestingly, many of these factors may be altered at the genetic level by means of congenital atherosclerotic-related plymorphisms[@b70-vhrm-8-533]--[@b72-vhrm-8-533] and genetic determinants of aortic aneurysms.[@b73-vhrm-8-533] Moreover, even acquired mutations have been postulated to modulate these facts.[@b74-vhrm-8-533]

TGF-β1 in myeloproliferative syndromes
--------------------------------------

Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocytosis, essential myelofibrosis) are clonal hematological neoplasms in which an increased risk of arterial thrombosis occurs. A growing body of clinical and experimental evidence suggests that these variable phenotypes can follow a graded natural history, from initial essential thrombocytosis to subsequent polycythemia vera, and eventual spent-phase secondary myelofibrosis.[@b75-vhrm-8-533] These three disorders are associated with increased risk of arterial thrombosis, and in polycythemia vera, this risk is 20% at 10 years.[@b75-vhrm-8-533]

In essential thrombocytosis, the abnormal clone seems to lose sensitivity to the proliferation-control effects of TGF-β1.[@b76-vhrm-8-533] In polycythemia vera, the abnormal clone equally loses response to the cytokine.[@b77-vhrm-8-533]

However, essential or secondary myelofibrosis is the chronic myeloproliferative syndrome which is associated with the shortest survival rate.[@b78-vhrm-8-533] The risk of thrombosis is similar to that found in essential thrombocythemia (1%--3% per patient per year).[@b79-vhrm-8-533] This is the variant of myeloproliferative syndrome which has the strongest link to dysregulation of the TGF-β1 pathway.[@b78-vhrm-8-533] In fact, TGF-β increases myelofibrosis in murine models.[@b80-vhrm-8-533] In cell culture models, TGF-β secretion seems to be regulated by NFκB.[@b81-vhrm-8-533] In myeloproliferative syndromes, there seems to be a progressive grading in TGF-β1 in the prefibrotic state, although established myelofibrosis has lower TGF-β1 levels.[@b82-vhrm-8-533] Higher TGF-β levels seem to be correlated with increased allelic charge of JAK2, and decreased EPC levels.[@b82-vhrm-8-533],[@b83-vhrm-8-533]

Therapy of myelofibrosis is a clinical challenge and supportive care has been the only treatment to date.[@b77-vhrm-8-533] Current JAK-2 inhibitors have shown only a limited benefit in regard to spleen size.[@b84-vhrm-8-533] Advances in the knowledge of TGF-β signaling in myeloproliferative syndromes may guide the choice of synergistic novel therapies such as small-molecule TGF-β pathway blockers including, SB-431542/ALK-4 inhibitor of the ALK-4 kinase activity[@b2-vhrm-8-533], heat-shock protein inhibitors, NFκB inhibitors,[@b85-vhrm-8-533] or epigenetic drugs.[@b86-vhrm-8-533]

Thus, progressive TGF-β dysfunction can be considered as a shared pathogenic event in atherosclerosis and Philadelphia-negative myeloproliferative syndromes, and a putative diagnostic and therapeutic tool.

Conclusion
==========

TGF-β1 is a key factor in diseases affected by cardiovascular disorders, such as atherosclerosis and myeloproliferative syndromes. The current knowledge of the complex TGF-β1 regulation of physiological and pathological processes may help to design novel diagnostic techniques and target-designed innovative therapies.
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![Summary of the main regulators of the TGF-β pathway.\
**Notes:** Briefly, TGF-β binds to receptor type 2 and phosphorylates the type 1 receptor, whose main isoform is termed ALK-4 (activin-like kinase). This kinase phosphorylates and activates Smad2 or Smad3, which forms a heterodimer with Smad4, and internalizes into the nucleus to regulate gene expression. TGF-β can also act by means of non-Smad mediators, such as p38 MAP kinase and Small GTPases, like RhoA. Cytoskeleton and receptor endocytosis are additional mechanisms to regulate the TGF-β signaling. Gene expression can also be eventually modified by micro-RNAs.\
**Abbreviatons:** TGF-β, transforming growth factor beta; Smad, second messenger protein; ALKs, activin-like kinases.](vhrm-8-533f1){#f1-vhrm-8-533}
